";s:4:"text";s:5432:" The craving score, which was between 62.4 and 65.6 before treatment, decreased at the end of the study to 29.8 with Suboxone, compared with 55.1 with placebo.The most common side effects with Suboxone (seen in more than 1 patient in 10) are insomnia (difficulty sleeping), constipation, nausea (feeling sick), sweating, headache and withdrawal syndrome.For the full list of all side effects reported with Suboxone, see the package leaflet.Suboxone should not be used in people who may be hypersensitive (allergic) to buprenorphine or naloxone, or to any of the other ingredients. We comply with the HONcode standard for trustworthy health information - Patients also used a specially designed questionnaire to record their cravings, and the change in the questionnaire score before and at the end of the study was measured.Suboxone was as effective as buprenorphine on its own and more effective than placebo: 17.8% of the patients who received Suboxone had a urine sample that tested negative at the end of the study, compared with 5.8% of the patients receiving placebo. It must also not be used in patients with acute alcohol intoxication (excessive alcohol consumption) or delirium tremens (a condition caused by alcohol withdrawal).The CHMP noted that the combination of an opioid analogue with an opioid antagonist is an established strategy for reducing the potential misuse of the medicine. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their … Available for Android and iOS devices. For full details, see the summary of product characteristics (also part of the EPAR).Suboxone contains two active substances: buprenorphine, a partial opioid agonist (it acts like an opioid drug), and naloxone, an opioid antagonists (it counteracts the effects of opioid drugs).Sublingual tablets containing buprenorphine alone have been available in the EU since the mid-1990s for the treatment of opioid addiction. Once the patient has been stabilised, the maintenance dose may be reduced gradually and eventually treatment may be stopped.The effectiveness of Suboxone treatment depends on the patient also receiving other medical, social and psychological support. For Suboxone, you don’t need to go to a clinic to receive treatment. This means that because the medicine can be misused or cause addiction, it is used under stricter conditions than normal.Suboxone must be used under the supervision of a doctor who has experience in the management of opioid addiction. Suboxone is used in adults and children over 15 years of age, who are also receiving medical, social and psychological support.The medicine can only be obtained by ‘special’ prescription. A risk management plan has been developed to ensure that Suboxone is used as safely as possible.